VYNE Therapeutics Inc.
For every therapeutic challenge, we question traditional assumptions and find better solutions.
Bridgewater, United States
52 employees
Post Ipo Equity
Total: $297.84M
Health Care, Health and Wellness +1
General Information
Get notified when VYNE Therapeutics Inc. moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track VYNE Therapeutics Inc.
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Health Care
About VYNE Therapeutics Inc.
Taxonomy: biopharmaceutical, clinical late-stage, dermatologic conditions, immuno-inflammatory, serlopitant, pruritus, atopic dermatitis, psoriasis, prurigo nodularis, innovative therapies, patient-centric, therapeutic solutions, skin health, immunology, medical innovation
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | 8 |
|
30 Oct 2023 |
| Post-IPO Equity | •••••• | - | 26 Jan 2021 | |
| Post-IPO Equity | •••••• | - | 05 Jun 2020 | |
| Series C | •••••• | 9 |
|
18 Jul 2017 |
| Series B | •••••• | 4 |
|
01 Nov 2015 |
VYNE Therapeutics Inc. Alternatives & Competitors
Transforming lives with Treg therapies
The ChemoCentryx LinkedIn page is no longer active or monitored.
Dedicated to improving the lives of patients with liver diseases
vs
13therapeutics
FAQ About VYNE Therapeutics Inc.
Don't just browse. Track.
Signal Tracker monitors VYNE Therapeutics Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.
